Ergoteles’s ALX Oncology ALXO Stock Holding History

Ergoteles’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,415	Closed	-$101K	–	1021
2023 Q1	$101K	Buy	+22,415	New	+$170K	﹤0.01%	1101
2022 Q3	–	Sell	-66,600	Closed	-$539K	–	1520
2022 Q2	$539K	Buy	+66,600	New	+$725K	0.02%	808

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ergoteles's ALXO Position: Q2 2023 in Review

Ergoteles sold out of ALX Oncology (ALXO) in Q2 2023, closing a stake of 22,415 shares — an estimated $101K sold.

Ergoteles first reported a position in ALXO in Q2 2022 and held it in 2 quarters. The position peaked at $539K in Q2 2022. 75 funds tracked by Wall St. Rank hold ALXO as of Q2 2023.

Ergoteles reported no remaining ALX Oncology position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 22,415 ALX Oncology shares in Q2 2023, an estimated $101K.
Ergoteles first reported a position in ALX Oncology in Q2 2022 and held it in 2 quarters.
Ergoteles's ALX Oncology position peaked at $539K in Q2 2022.
75 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.